Talquetamab delivers high response rates in refractory myeloma; learn how to prevent skin, nail and oral side effects to stay on therapy. As the therapeutic arsenal for relapsed/refractory multiple ...
Severe CRS appeared numerically less frequent than in ZUMA-3, suggesting potential differences in patient selection, supportive care, grading, or real-world mitigation strategies. Tocilizumab and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results